Non-regulatory
announcement
ONDINE BIOMEDICAL
INC.
("Ondine
Biomedical", "Ondine", or the "Company")
Steriwave in first Australian
hospital
Mater Hospital, North Sydney
has become the first Australian hospital to use Ondine Biomedical's
award-winning light-activated antimicrobial
technology
Ondine Biomedical Inc. (LON: OBI), the Canadian life
sciences company pioneering light-activated antimicrobial
treatments, announces that Mater Hospital, North Sydney, a private
hospital in New South Wales, has become the first Australian
hospital to start using its light-activated antimicrobial
Steriwave® technology to prevent the spread of hospital-acquired
infections (HAIs). Mater Hospital, located in North Sydney and
founded in 1906, is part of St. Vincent's Health Australia Group,
Australia's largest not-for-profit provider of health and aged care
services.
Medical Oncologist, Professor Frances Boyle AM,
Director of the Patricia Ritchie Centre for Cancer Care and
Research at Mater Hospital and Professor of Medical Oncology at the
University of Sydney, said: "We are very pleased to be the first
hospital in Australia to have the Steriwave nasal decolonization
system. The pathogens patients carry have long been known to cause
hospital-acquired infections, especially for the weak and
immunocompromised. Having a rapid non-antibiotic approach to
decolonizing the nose - a major source of infection transmission -
is a benefit to our patients."
Orthopaedic Spine Surgeon Dr John Street, Director of
the Integrated Ambulatory Spine Program at Vancouver Coastal Health
and upcoming President of the Canadian Spine Society, was a keynote
speaker at the recent 2024
Spine Society of Australia 35th Annual Scientific Meeting
that was held in Sydney on April 5-7th,
2024. Dr Street presented the results of his team's 14-year study
evaluating Steriwave's effect on SSIs following spine surgery
at Vancouver General Hospital ("VGH"), concluding that Steriwave
nasal photodisinfection should be part of routine use and
recommended it as standard of care for all elective and emergent
spine surgeries.
The VGH research involved 13,493 patients and
demonstrated a 66.5% reduction (7.98% vs 2.67%, p<0.001) in
surgical site infections (SSIs) following spine surgery when
Ondine's Steriwave nasal photodisinfection (nPDT) was implemented
in the universal pre-surgical infection prevention protocol. The
researchers also found average net annual cost saving of $2.49
million, a saving of over $2,400 per spine surgery patient, post
rollout.
**ENDS**
Enquiries:
|
Ondine Biomedical
Inc.
|
|
|
Carolyn Cross, CEO
|
+001 (604) 665 0555
|
|
|
|
|
Singer Capital Markets
(Nominated Adviser and Joint Broker)
|
|
|
Aubrey Powell, Sam
Butcher
|
+44 (0)20 7496 3000
|
|
|
|
|
RBC
Capital Markets (Joint Broker)
|
|
|
Rupert Walford, Kathryn
Deegan
|
+44 (0)20 7653 4000
|
|
|
|
|
Vane Percy & Roberts (Media Contact)
|
|
|
Simon Vane Percy, Amanda
Bernard
|
+44 (0)77 1000 5910
|
About Ondine
Biomedical Inc.
Ondine Biomedical Inc. is a Canadian life sciences
company and leader innovating light-activated antimicrobial
therapies (also known as 'photodisinfection'). Ondine has a
pipeline of investigational products, based on its proprietary
photodisinfection technology, in various stages of development.
Ondine's nasal photodisinfection system has a CE mark
in Europe and the UK and is approved in Canada and several other
countries under the name Steriwave®. In the US, it has been granted
Qualified Infectious Disease Product designation and Fast Track
status by the FDA and is currently undergoing clinical trials for
regulatory approval. Products beyond nasal photodisinfection
include therapies for a variety of medical indications such as
chronic sinusitis, ventilator-associated pneumonia, burns, and many
other indications.
About
Steriwave®
Ondine's Steriwave® nasal photodisinfection system is
a patented technology using a proprietary light-activated
antimicrobial (photosensitizer) to destroy bacteria, viruses, and
fungi colonizing the nose. The photodisinfection treatment is
carried out by a trained healthcare professional and is an easy to
use, painless, two-step process. The photosensitizer is applied to
each nostril using a nasal swab, followed by illumination of the
area with a specific wavelength of red laser light for less than
five minutes. The light activates the photosensitizer, causing an
oxidative burst that is lethal to all types of pathogens without
causing long-term adverse effects on the nasal microbiome. A key
benefit of this approach-unlike with antibiotics, which have
resistance rates reported as high as 81%[1]-is
that pathogens do not develop resistance to the therapy.
Nasal decolonization is recommended in the 2016 WHO
Global guidelines for the prevention of surgical site
infections,[2] and the Society for
Healthcare Epidemiology of America (SHEA) guidelines, published in
May 2023, recommend nasal decolonization for major surgical
procedures.[3]
[1] Poovelikunnel T, Gethin G, Humphreys H. Mupirocin resistance:
clinical implications and potential alternatives for the
eradication of MRSA. J Antimicrob Chemother.
2015;70(10):2681-2692. doi:10.1093/jac/dkv169
[2] https://cdn.who.int/media/docs/default-source/integrated-health-services-(ihs)/ssi/fact-sheet-staphylococcus-web.pdf?sfvrsn=7e7266ed_2
[3] Calderwood MS, Anderson DJ, Bratzler DW, et al. Strategies to
prevent surgical site infections in acute-care hospitals: 2022
Update. Infect Control Hosp Epidemiol. 2023;44(5):695-720.
doi:10.1017/ice.2023.67